In conclusion, this study demonstrates that elevation in the serum inflammatory biomarkers CRP or SAA drawn randomly during treatment in the adjuvant setting are significantly and independently associated with increased risk of relapsed HR+/HER2− breast cancer, but not HR+/HER2+ breast cancer. This evidence concerns the gene ERBB2 and breast cancer.